Market Research Logo

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

Summary


Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men and women equally. Although, early diagnosis and intervention are key in preventing irreversible joint damage, many PsA patients are undiagnosed and go untreated for months or years.

GlobalData projects the PsA market in 7MM to experience strong growth during the forecast period at a CAGR of 10.74%. By the forecast's end in 2025, sales will increase to over $12.58 billion from $4.53 billion in 2015. This growth will be driven primarily by the increase in diagnosed prevalent cases from 1,044,022 in 2015 to 1,520,471 in 2025. Further, the launch of the IL-17 inhibitors, including Novartis' Cosentyx, Eli Lilly's Taltz, and AstraZeneca's Lumicef, as well as the launch of Celgene's oral therapy Otezla, will expand the treatment armamentarium for PsA driving growth in the market.

Highlights

Key Questions Answered

  • How large an impact will biosimilars have on the PsA market? What do dermatologists, rheumatologists, and key opinion leaders across the 7MM think about the evolving treatment landscape?
  • What opportunities remain in the market for new product entrants?
  • What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the PsA market?
  • According to KOLs, what are the most important unmet needs in PsA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2025?
  • What clinical and commercial factors are likely to affect uptake of PsA therapies in the US, 5EU, and Japan?
Key Findings
  • The PsA market is currently very dynamic, with effective biologic therapies recently approved, including interleukin-17 (IL-17) inhibitors - Cosentyx, Taltz, and Lumicef - and oral phosphodiesterase-4 (PDE4) - Otezla.
  • Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market.
  • The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnson’s Remicade (infliximab), AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Stelara (ustekinumab).
  • The drivers for market growth will include the increasing diagnosis rate as well as the recent approval of novel therapies. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share.
Scope
  • Overview of PsA, including epidemiology, etiology, pathophysiology, symptoms and country-specific diagnosis and treatment recommendations.
  • Annualized PsA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the PsA market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of novel products- including promising IL-17 inhibitors - and biosimilars - such as Celltrion’s Hospira, Sandoz’s Erelzi, Biogen/Samsung Bioepies’ Flixabi and Benepali, and Amgen’s Amjevita.
  • Analysis of the current and future market competition in the global PsA market (7MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Psoriasis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Psoriasis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PsA market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for PsA (2015-2025)
4.5.1 Diagnosed Prevalent Cases of PsA
4.5.2 Age-Specific Diagnosed Prevalent Cases of PsA
4.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA
4.5.4 Age-Standardized Diagnosed Prevalence of PsA
4.5.5 Diagnosed Prevalent Cases by Type
4.5.6 Diagnosed Prevalent Cases by Joint Involvement
4.6 Alternative Forecast of Diagnosed Prevalent Cases of PsA
4.7 Discussion
4.7.1 Epidemiological Forecast Insight
4.7.2 Limitations of the Analysis
4.7.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Diagnosis
5.1.2 Disease Activity
5.1.3 Treatment Guidelines and Leading Prescribed Drugs
5.1.4 Clinical Practice
5.2 US
5.3 5EU
5.4 Japan
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Major Brands
6.2.1 Enbrel (etanercept)
6.2.2 Humira (adalimumab)
6.2.3 Simponi (golimumab)
6.2.4 Remicade (infliximab)
6.2.5 Cimzia (certolizumab pegol)
6.2.6 Cosentyx (secukizumab)
6.2.7 Lumicef (brodalumab)
6.2.8 Taltz (ixekizumab)
6.2.9 Stelara (ustekinumab)
6.2.10 Otezla (apremilast)
6.3 Other Therapeutic Classes
7 Unmet Needs and Opportunities
7.1 Overview
7.2 Increased Awareness Among Dermatologists and Primary Care Physicians
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Early Diagnosis and Treatment
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Improved Drug Safety and Efficacy Profiles
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Development of Cost-Effective Therapies
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Class
8.3 Promising Drugs in Clinical Development
8.3.1 Xeljanz (tofacitinib)
8.3.2 Orencia (abatacept)
8.3.3 Clazakizumab
8.4 Other Drugs in Development
8.5 Biosimilars
8.5.1 Introduction
8.5.2 Biosimilars Versus Branded Biologics in Key Autoimmune Diseases
8.5.3 Biosimilars in the Immunology Community
8.5.4 By the Numbers: Biosimilars in Development
8.5.5 The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry
8.5.6 Uptake of Biosimilars is Expected to Vary by Market
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Amgen
9.3.2 AbbVie
9.3.3 Johnson & Johnson
9.3.4 UCB
9.3.5 Novartis
9.3.6 Celgene
9.3.7 Pfizer
9.3.8 Bristol-Myers Squibb
9.3.9 AstraZeneca
9.3.10 Eli Lilly
9.3.11 Alder
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Psoriatic Arthritis Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Generic Erosion
11.4.8 Pricing of Pipeline Agents
11.5 Primary Research - Key Opinion Leaders Interviewed for This Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Therapy Area Director
11.7.3 Epidemiologist
11.7.4 Global Director of Therapy Analysis and Epidemiology
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Symptoms of PsA
Table 2: Risk Factors for and Comorbidities of PsA
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PsA
Table 4: Sources Used to Forecast Proportion of Diagnosed Prevalent Cases of PsA by Type
Table 5: 7MM, Diagnosed Prevalent Cases of PsA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
Table 6: 7MM, Age-Specific, Diagnosed Prevalent Cases of PsA, Both Sexes, N (Row %), 2015
Table 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PsA, Ages ≥18, N (Row %), 2015
Table 8: 7MM, Alternative Diagnosed Prevalent Cases of PsA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
Table 9: CASPAR Diagnostic Criteria for PsA
Table 10: Treatment Guidelines for PsA
Table 11: Overarching Principles of PsA GRAPPA Treatment Recommendations, 2015
Table 12: GRAPPA Treatment Guidelines for PsA, 2015
Table 13: Updated EULAR Overarching Principles for PsA, 2015
Table 14: Updated EULAR Recommendations for the Management of PsA, 2015
Table 15: Country Profile - US
Table 16: Country Profile - 5EU
Table 17: Country Profile - Japan
Table 18: Leading Branded Treatments for PsA, 2015
Table 19: Product Profile - Enbrel
Table 20: Enbrel SWOT Analysis, 2015
Table 21: Product Profile - Humira
Table 22: Humira SWOT Analysis, 2015
Table 23: Product Profile - Simponi
Table 24: Simponi SWOT Analysis, 2015
Table 25: Product Profile - Remicade
Table 26: Remicade SWOT Analysis, 2015
Table 27: Product Profile - Cimzia
Table 28: Cimzia SWOT Analysis, 2015
Table 29: Product Profile - Cosentyx
Table 30: Cosentyx SWOT Analysis, 2015
Table 31: Product Profile - Lumicef
Table 32: Lumicef SWOT Analysis, 2015
Table 33: Product Profile - Taltz
Table 34: Taltz SWOT Analysis, 2015
Table 35: Product Profile - Stelara
Table 36: Stelara SWOT Analysis, 2015
Table 37: Product Profile - Otezla
Table 38: Otezla SWOT Analysis, 2015
Table 39: Summary of Minor Therapeutic Classes for PsA, 2016
Table 40: Unmet Needs and Opportunities in PsA
Table 41: Comparison of Therapeutic Classes in Development for PsA, 2016
Table 42: Product Profile - Xeljanz
Table 43: Clinical Trials Demonstrating Xeljanz as a Potential Treatment for PsA
Table 44: Xeljanz SWOT Analysis, 2015
Table 45: Product Profile - Orencia
Table 46: Orencia SWOT Analysis, 2015
Table 47: Product Profile - Clazakizumab
Table 48: Clazakizumab SWOT Analysis, 2015
Table 49: Drugs in Development for PsA, 2016
Table 50: Clinical Trials Demonstrating the Efficacy of Biosimilars to Branded Biologics
Table 51: 7MM, Marketed and Pipeline Biosimilars for PsA, 2016
Table 52: 7MM, Physician Uptake of Biosimilar Products for PsA, 2016
Table 53: 7MM, Key Companies in the PsA Market, 2015
Table 54: Amgen’s PsA Portfolio Assessment, 2015
Table 55: AbbVie’s PsA Portfolio Assessment, 2015
Table 56: J&J’s PsA Portfolio Assessment, 2015
Table 57: UCB’s PsA Portfolio Assessment, 2015
Table 58: Novartis’ PsA Portfolio Assessment, 2015
Table 59: Celgene’s PsA Portfolio Assessment, 2015
Table 60: Pfizer’s PsA Portfolio Assessment, 2015
Table 61: BMS’ PsA Portfolio Assessment, 2015
Table 62: AstraZeneca’s PsA Portfolio Assessment, 2015
Table 63: Eli Lilly’s PsA Portfolio Assessment, 2015
Table 64: Alder’s PsA Portfolio Assessment, 2015
Table 65: PsA Market - Global Drivers and Barriers, 2015‒2025
Table 66: Key Events Impacting Sales for PsA in the US, 2015-2015
Table 67: PsA Market - US Drivers and Barriers, 2015‒2025
Table 68: Key Events Impacting Sales for PsA in the 5EU, 2015-2015
Table 69: PsA Market - 5EU Drivers and Barriers, 2015‒2025
Table 70: Key Events Impacting Sales for PsA in Japan, 2015-2015
Table 71: PsA Market - Japan Drivers and Barriers, 2015‒2025
Table 72: 7MM, Key Launch Dates
Table 73: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of PsA, Ages ≥18 Years, Both Sexes, N, 2015-2025
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of PsA, Both Sexes, N, 2015
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of PsA, Ages ≥18, 2015
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence Rate of PsA, Ages ≥18, N, 2015
Figure 5: 7MM, Diagnosed Prevalent Cases of PsA by Type, Both Sexes, Ages ≥18, 2015
Figure 6: 7MM, Diagnosed Prevalent Cases of PsA by Joint Involvement, Both Sexes, Ages ≥18, 2015
Figure 7: 7MM, Alternative Diagnosed Prevalent Cases of PsA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
Figure 8: Original GRAPPA Treatment Guidelines for PsA, 2009
Figure 9: EULAR 2015 Recommendations for the Management of PsA, Phase I
Figure 10: EULAR 2015 Recommendations for the Management of PsA, Phase II
Figure 11: EULAR 2015 Recommendations for the Management of PsA, Phase III
Figure 12: EULAR 2015 Recommendations for the Management of PsA, Phase IV
Figure 13: PsA Clinical Trials by Drug Class, 2016
Figure 14: PsA - Phase IIb-III Pipeline, 2016
Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in PsA, 2015-2025
Figure 16: Clinical and Commercial Positioning of Xeljanz
Figure 17: Clinical and Commercial Positioning of Orencia
Figure 18: Clinical and Commercial Positioning of Clazakizumab
Figure 19: Biosimilar Prescribing Habits in PsA Across the 7MM, 2016
Figure 20: Global Sales of Branded Products for PsA by Company, 2015-2025
Figure 21: Company Portfolio Gap Analysis in PsA, 2015-2025
Figure 22: Global Sales for PsA by Region, 2015-2025
Figure 23: US Sales for PsA by Drug Class, 2015-2025
Figure 24: 5EU Sales for PsA by Drug Class, 2015-2025
Figure 25: Japan Sales for PsA by Drug Class, 2015-

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report